



**QUEEN'S  
UNIVERSITY  
BELFAST**

## **Erratum to: 'Effectiveness of biomarker-based exclusion of ventilator-acquired pneumonia to reduce antibiotic use (VAPrapid-2): study protocol for a randomised controlled trial'**

Hellyer, T. P., Anderson, N. H., Parker, J., Dark, P., Van Den Broeck, T., Singh, S., McMullan, R., Agus, A. M., Emerson, L. M., Blackwood, B., Gossain, S., Walsh, T. S., Perkins, G. D., Morris, A. C., McAuley, D. F., & Simpson, A. J. (2016). Erratum to: 'Effectiveness of biomarker-based exclusion of ventilator-acquired pneumonia to reduce antibiotic use (VAPrapid-2): study protocol for a randomised controlled trial'. *Trials*, 17(465), 1. <https://doi.org/10.1186/s13063-016-1594-8>

**Published in:**  
Trials

**Document Version:**  
Publisher's PDF, also known as Version of record

**Queen's University Belfast - Research Portal:**  
[Link to publication record in Queen's University Belfast Research Portal](#)

### **Publisher rights**

Copyright 2018 the authors.

This is an open access article published under a Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.

### **General rights**

Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

### **Take down policy**

The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact [openaccess@qub.ac.uk](mailto:openaccess@qub.ac.uk).

ERRATUM

Open Access



# Erratum to: 'Effectiveness of biomarker-based exclusion of ventilator-acquired pneumonia to reduce antibiotic use (VAPrapid-2): study protocol for a randomised controlled trial'

Thomas P. Hellyer<sup>1\*</sup>, Niall H. Anderson<sup>2</sup>, Jennie Parker<sup>3</sup>, Paul Dark<sup>4</sup>, Tina Van Den Broeck<sup>5</sup>, Suveer Singh<sup>6</sup>, Ronan McMullan<sup>7</sup>, Ashley M. Agus<sup>8</sup>, Lydia M. Emerson<sup>9</sup>, Bronagh Blackwood<sup>9</sup>, Savita Gossain<sup>10</sup>, Tim S. Walsh<sup>11</sup>, Gavin D. Perkins<sup>12</sup>, Andrew Conway Morris<sup>13</sup>, Daniel F. McAuley<sup>2,8,14</sup> and A. John Simpson<sup>1</sup>

## Erratum

Unfortunately, the original version of this article [1] contained an error. There are two references in the text to the threshold for defining VAP as greater than  $10^4$  colony forming units/ml. These should read greater OR EQUAL to  $10^4$  colony forming units/ml. The error is in the abstract and in the intervention sections.

In the abstract, please replace:

Patients with clinically suspected VAP undergo BAL and VAP is confirmed by growth of a potential pathogen at  $>10^4$  colony forming units per millilitre (CFU/ml).

With the following correct version:

Patients with clinically suspected VAP undergo BAL and VAP is confirmed by growth of a potential pathogen at  $\geq 10^4$  colony forming units per millilitre (CFU/ml).

In the Interventions, please replace:

VAP is confirmed by the widely used threshold of growth of a potential pathogen at  $>10^4$  colony forming units per ml (CFU/ml)(13).

With the following correct version:

VAP is confirmed by the widely used threshold of growth of a potential pathogen at  $\geq 10^4$  colony forming units per ml (CFU/ml)(13).

## Author details

<sup>1</sup>Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK. <sup>2</sup>Centre for Population Health Sciences, University of Edinburgh, Medical School, Edinburgh, UK. <sup>3</sup>Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, UK. <sup>4</sup>Institute of Inflammation and Repair, University of

Manchester, Manchester Academic Health Sciences Centre & Intensive Care Unit, Salford Royal NHS Foundation Trust, Greater Manchester, UK. <sup>5</sup>Becton Dickinson Biosciences, Erembodegem, Aalst, Belgium. <sup>6</sup>Intensive Care Unit, Chelsea and Westminster Hospital, Imperial College London, London, UK. <sup>7</sup>Department of Medical Microbiology, Kelvin Building, The Royal Hospitals, Belfast, UK. <sup>8</sup>Northern Ireland Clinical Trials Unit, Elliot Dynes Building, The Royal Hospitals, Belfast, UK. <sup>9</sup>Centre for Experimental Medicine, Queen's University Belfast, Belfast, UK. <sup>10</sup>Public Health Laboratory, Heart of England NHS Foundation Trust, Birmingham, UK. <sup>11</sup>MRC Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK. <sup>12</sup>University of Warwick and Heart of England NHS Foundation Trust, Coventry, UK. <sup>13</sup>Division of Anaesthesia, Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, UK. <sup>14</sup>Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, UK.

Received: 30 August 2016 Accepted: 13 September 2016

Published online: 26 September 2016

## Reference

1. Hellyer TP, Anderson NH, Jennie P, Paul D, Tina Van Den B, Suveer S, Ronan MM, Agus AM, Emerson LM, Bronagh B, Savita G, Walsh TS, Perkins GD, Conway Morris A, McAuley DF, Simpson AJ. Effectiveness of biomarker-based exclusion of ventilator-acquired pneumonia to reduce antibiotic use (VAPrapid-2): study protocol for a randomised controlled trial. *Trials*. 2016;17:318.

\* Correspondence: t.p.hellyer@ncl.ac.uk

<sup>1</sup>Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK

Full list of author information is available at the end of the article